Resistance to anti-viral drug may be more likely in cystic fibrosis patients

Following lung transplantation, resistance to the anti-viral drug ganciclovir may be more likely in cystic fibrosis patients, scientists report. Ganciclovir is given to lung transplant patients to protect against a life-threatening virus that is common after transplantation, and reduces mortality due to the virus from 34 percent to between 3 and 6 percent. But between 5 percent and 10 percent of patients infected with the virus have strains that are resistant to the drug.



from Today's Healthcare News -- ScienceDaily http://ift.tt/1AQfLtT